Erratum: Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations (European Journal of Clinical Pharmacology DOI: 10.1007/s00228-010-0831-4);Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations

European Journal of Clinical Pharmacology

Volumn 66, Issue 9, 2010, Pages 859-864

  Gaedigk, Andrea ^a   Isidoro García, Maria ^b   Pearce, Robin E ^a   Sánchez, Santiago ^b   García Solaesa, Virginia ^b   Lorenzo Romo, Carolina ^b   Gonzalez Tejera, Gloria ^c   Corey, Susan ^c  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

AmpliChip CYP450 test; CYP2D6; CYP2D6*31; Dextromethorphan; Phenotype

Indexed keywords

ANTIDEPRESSANT AGENT; BICALUTAMIDE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; NEUROLEPTIC AGENT; ORAP FORTE; PIMOZIDE; RISPERIDONE; UNCLASSIFIED DRUG; WICK FORMEL 44 PLUS;

AFRICAN AMERICAN; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; DRUG METABOLISM; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUERTO RICO; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPAIN; UNITED STATES;

EID: 77956188003     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0946-7     Document Type: Erratum

References (17)

1. J Sistonen A Sajantila O Lao J Corander G Barbujani S Fuselli 2007 CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure Pharmacogenet Genomics 17 2 93 101 1:CAS:528:DC%2BD2sXhslCmtr0%3D 17301689
2. UM Zanger S Raimundo M Eichelbaum 2004 Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn Schmiedebergs Arch Exp Pathol Pharmacol 369 23 37 10.1007/s00210-003-0832-2 1:CAS:528: DC%2BD2cXitF2hsQ%3D%3D 14618296
3. UM Zanger M Turpeinen K Klein M Schwab 2008 Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation Anal Bioanal Chem 392 1093 1108 10.1007/s00216-008-2291-6 1:CAS:528:DC%2BD1cXht1yqsbjP 18695978
4. D Marez M Legrand N Sabbagh J-M Guidice C Spire J-J Lafitte, et al. 1997 Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution Pharmacogenetics 7 193 202 10.1097/00008571-199706000-00004 1:CAS:528:DyaK2sXkvFymtLk%3D 9241659
5. D Allorge D Breant J Harlow J Chowdry JM Lo-Guidice D Chevalier, et al. 2005 Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution Proteins 59 2 339 346 10.1002/prot.20399 1:CAS:528:DC%2BD2MXksl2jsrc%3D 15726636
6. RocheMolecularSystems. AmpliChip CYP450 Test. 2008;CE-IVD
7. A Gaedigk LD Bradford KA Marcucci JS Leeder 2002 Unique CYP2D6 activity distribution and genotype-phenotype discordance in African Americans Clin Pharmacol Ther 72 76 89 10.1067/mcp.2002.125783 1:CAS:528:DC%2BD38Xms1altrw%3D 12152006
8. JS Leeder RE Pearce A Gaedigk A Modak DI Rosen 2008 Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype J Clin Pharmacol 48 9 1041 1051 10.1177/0091270008319709 1:CAS:528:DC%2BD1cXhtFaqs7nN 18728242
9. MJ Blake A Gaedigk RE Pearce LR Bomgaars ML Christensen C Stowe, et al. 2007 Ontogeny of dextromethorphan O-and N-demethylation in the first year of life Clin Pharmacol Ther 81 4 510 516 10.1038/sj.clpt.6100101 1:CAS:528:DC%2BD2sXkvFymu7w%3D 17301735
10. A Gaedigk SD Simon RE Pearce LD Bradford MJ Kennedy JS Leeder 2008 The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype Clin Pharmacol Ther 83 234 242 10.1038/sj.clpt.6100406 1:STN:280:DC%2BD1c%2FkslCqug%3D%3D 17971818
11. N Yasui-Furukori M Hidestrand E Spina G Facciola MG Scordo G Tybring 2001 Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes Drug Metab Dispos 29 10 1263 1268 1:CAS:528: DC%2BD3MXntVGqtbY%3D 11560868
12. CB Eap G Bondolfi D Zullino C Bryois M Fuciec L Savary, et al. 2001 Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test Ther Drug Monit 23 3 228 231 10.1097/00007691-200106000-00008 1:CAS:528:DC%2BD3MXks12jtbk%3D 11360030
13. T Heller J Kirchheiner VW Armstrong H Luthe M Tzvetkov J Brockmoller, et al. 2006 AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping Ther Drug Monit 28 5 673 677 10.1097/01.ftd. 0000246764.67129.2a 1:CAS:528:DC%2BD28XhtVKrtL3K 17038884
14. MC Rebsamen J Desmeules Y Daali A Chiappe A Diemand C Rey, et al. 2009 The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction Pharmacogenomics J 9 1 34 41 10.1038/tpj.2008.7 1:CAS:528: DC%2BD1MXotFWhsQ%3D%3D 18591960
15. J de Leon MT Susce M Johnson M Hardin L Maw A Shao, et al. 2009 DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping CNS Spectr 14 1 19 34 19169185
16. KA Candiotti Z Yang Y Rodriguez A Crescimone GC Sanchez P Takacs, et al. 2009 The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption Pain Med 10 5 799 805 10.1111/j.1526-4637.2009.00641.x 19523031
17. SM Adams E Bosch PL Balaresque SJ Ballereau AC Lee E Arroyo, et al. 2008 The genetic legacy of religious diversity and intolerance: paternal lineages of Christians, Jews, and Muslims in the Iberian Peninsula Am J Hum Genet 83 6 725 736 10.1016/j.ajhg.2008.11.007 1:CAS:528:DC%2BD1MXit1Gq 19061982